Literature DB >> 11427955

Some issues in resolution of diagnostic tests using an imperfect gold standard.

D M Hawkins1, J A Garrett, B Stephenson.   

Abstract

As a subject's true disease status is seldom known with certainty, it is necessary to compare the performance of new diagnostic tests with those of a currently accepted but imperfect 'gold standard'. Errors made by the gold standard mean that the sensitivity and specificity calculated for the new test are biased, and do not correctly estimate the new method's sensitivity and specificity. The traditional approach to this problem was 'discrepant resolution', in which the subjects for whom the two methods disagreed were subjected to a third 'resolver' test. Recent work has pointed out that this does not automatically solve the problem. A sounder approach goes beyond the discordant test results and tests at least some of the subjects with concordant results with the resolver also. This leaves some issues unresolved. One is the basic question of the direction of biases in various estimators. We point out that this question does not have a simple universal answer. Another issue, if one is to test a sample of the subjects with concordant results rather than all cases, is how to compute estimates and standard errors of the measures of test performance, notably sensitivity and specificity of the test method relative to the resolver. Expressions for these standard errors are given and illustrated with a numeric example. It is shown that using just a sample of subjects with concordant results may lead to great savings in assays. The design issue of how many concordant cells to test depends on the numbers of concordants and discordants. The formulae given show how to evaluate impact of different choices for these numbers and hence settle on a design that gives the required precision of estimates. Copyright 2001 John Wiley & Sons, Ltd.

Mesh:

Year:  2001        PMID: 11427955     DOI: 10.1002/sim.819

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  24 in total

Review 1.  Methods and recommendations for evaluating and reporting a new diagnostic test.

Authors:  A S Hess; M Shardell; J K Johnson; K A Thom; P Strassle; G Netzer; A D Harris
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-03-29       Impact factor: 3.267

Review 2.  The validation of screening tests: meet the new screen same as the old screen?

Authors:  Blase Gambino
Journal:  J Gambl Stud       Date:  2012-12

3.  Evidence of Misclassification of Drug-Event Associations Classified as Gold Standard 'Negative Controls' by the Observational Medical Outcomes Partnership (OMOP).

Authors:  Manfred Hauben; Jeffrey K Aronson; Robin E Ferner
Journal:  Drug Saf       Date:  2016-05       Impact factor: 5.606

4.  Comparative study of Kaposi's sarcoma-associated herpesvirus serological assays using clinically and serologically defined reference standards and latent class analysis.

Authors:  Maria Claudia Nascimento; Vanda Akico de Souza; Laura Masami Sumita; Wilton Freire; Fernando Munoz; Joseph Kim; Claudio S Pannuti; Philippe Mayaud
Journal:  J Clin Microbiol       Date:  2006-12-20       Impact factor: 5.948

5.  Utility of composite reference standards and latent class analysis in evaluating the clinical accuracy of diagnostic tests for pertussis.

Authors:  Andrew L Baughman; Kristine M Bisgard; Margaret M Cortese; William W Thompson; Gary N Sanden; Peter M Strebel
Journal:  Clin Vaccine Immunol       Date:  2007-11-07

6.  Properties of the Cannabis Abuse Screening Test (CAST) in the general population.

Authors:  Stéphane Legleye; Romain Guignard; Jean-Baptiste Richard; Kraus Ludwig; Alexander Pabst; François Beck
Journal:  Int J Methods Psychiatr Res       Date:  2015-06       Impact factor: 4.035

7.  Salivary extracellular RNA biomarkers for insulin resistance detection in hispanics.

Authors:  Yong Zhang; Jie Sun; Feng Li; Tristan R Grogan; Jose L Vergara; QingXian Luan; Moon-Soo Park; David Chia; David Elashoff; Kaumudi J Joshipura; David T W Wong
Journal:  Diabetes Res Clin Pract       Date:  2017-07-19       Impact factor: 5.602

8.  The Cannabis Abuse Screening Test and the DSM-5 in the general population: Optimal thresholds and underlying common structure using multiple factor analysis.

Authors:  Stéphane Legleye
Journal:  Int J Methods Psychiatr Res       Date:  2017-11-10       Impact factor: 4.035

9.  Performance of commercially available enzyme immunoassays for detection of antibodies against herpes simplex virus type 2 in African populations.

Authors:  Eddy van Dyck; Anne Buvé; Helen A Weiss; Judith R Glynn; David W G Brown; Bénédicte De Deken; John Parry; Richard J Hayes
Journal:  J Clin Microbiol       Date:  2004-07       Impact factor: 5.948

10.  Comparison of focus HerpesSelect and Kalon HSV-2 gG2 ELISA serological assays to detect herpes simplex virus type 2 antibodies in a South African population.

Authors:  Sinéad Delany-Moretlwe; Ute Jentsch; Helen Weiss; Jocelyn Moyes; Rhoda Ashley-Morrow; Wendy Stevens; Philippe Mayaud
Journal:  Sex Transm Infect       Date:  2009-10-16       Impact factor: 3.519

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.